MikeTrendsTrends right now

search

pharmaceutical companies

Trends

  1. 1
    Kobayashi Pharmaceutical weighs buyout offer above ¥500 billion●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deatMmastodonBusinessMarkets41 h ago

    Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The move would mark a major turning point for the company, which has faced reputational and financial fallout since the scandal, and is drawing attention to the future ownership of the troubled firm.

  2. 2
    European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines✉newsWorldEU Politics5 h ago

    European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.

  3. 3
    Meta paid ads promote Israeli settlement homes in West Bank●Meta runs paid ads promoting luxury homes in illegal Israeli settlements in the occupied West Bank. The same platform thMmastodonWarMiddle East621 h ago

    Meta is running paid advertisements promoting luxury homes in Israeli settlements in the occupied West Bank, according to reports circulating online. Critics point out the contradiction: the platform bans ads for counterfeit goods and unauthorized pharmaceuticals, yet accepts money from Israeli real estate companies marketing properties on Palestinian land. Settlements are considered illegal under international law, and the ads are drawing accusations that Meta is profiting from their promotion.

  4. 4
    Weight-loss jab maker sponsors Vogue World, drawing criticism●‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event✉newsHealth24 min ago

    Critics are raising concerns after Novo Nordisk, the maker of the weight-loss injection Wegovy, sponsored Vogue World, a high-profile fashion event tied to Vogue magazine. Commentators have called the partnership 'problematic', arguing that a pharmaceutical weight-loss company backing a leading fashion publication risks glamorising slimming drugs and reinforcing pressure around body image at a time when such jabs are already controversial.

  5. 5
    Anthropic quietly sets up AI-powered biology lab▼Anthropic creates AI powered wetlabYhnScienceBiology915 h ago

    Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.

  6. 6
    Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms●Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A✉newsScienceSpace Policy1 d ago

    Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.

  7. 7
    Arrowhead Pharmaceuticals Stock Nears Five-Year High on Phase 3 Win▼ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval✉newsBusinessRetail10 h ago

    Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results, with retail investors celebrating the biotech's momentum. The company is reportedly aiming for a broader FDA approval than initially expected, fueling optimism about the commercial potential of its drug pipeline and driving renewed interest in the stock.